hydroxyflutamide has been researched along with Prostatic Neoplasms in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.17) | 18.7374 |
| 1990's | 25 (34.72) | 18.2507 |
| 2000's | 30 (41.67) | 29.6817 |
| 2010's | 13 (18.06) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Budman, DR; Kreis, W; Liu, XM; Wang, LG | 2 |
| Attar, RM; Balog, A; Geng, J; Gottardis, MM; Hunt, JT; Martinez, R; Pickering, D; Rizzo, CA; Salvati, ME; Wei, DD; Weinmann, R | 1 |
| Dence, CS; Jenks, C; Katzenellenbogen, JA; Parent, EE; Sharp, TL; Welch, MJ | 1 |
| Attar, RM; Balog, A; Chandrasena, G; Fura, A; Furch, JA; Galella, MA; Geng, J; Giese, S; Gottardis, MM; Gougoutas, J; Jure-Kunkel, M; Krystek, SR; Mitt, T; Obermeier, M; Rampulla, R; Rizzo, CA; Salvati, ME; Shan, W; Vite, GD | 1 |
| Hashimoto, Y; Imai, K; Miyachi, H; Tanatani, A; Wakabayashi, K | 1 |
| Arnold, LA; Connelly, M; Féau, C; Guy, RK; Kosinski, A; Zhu, F | 1 |
| Badalassi, F; Bertozzi, F; Bradley, SR; Fejzic, A; Gardell, LR; Lewinsky, R; Lund, BW; Olsson, R; Pawlas, J; Piu, F; Schlienger, N; Tabatabaei, A; Thygesen, MB | 1 |
| Endo, Y; Fujii, S; Goto, T; Ohta, K; Ohta, S | 1 |
| Fournier, MA; Maltais, R; Poirier, D | 1 |
| Fujii, S; Hashimoto, Y; Hirano, T; Inoue, K; Ishigami-Yuasa, M; Kagechika, H; Kanai, M; Kawachi, E; Matsumura, M; Mori, S; Tanatani, A; Urushibara, K; Yura, K | 1 |
| Fujii, S; Ishigami-Yuasa, M; Kagechika, H; Kawachi, E; Kinoshita, M; Koga, H; Mori, S; Negishi, M; Tanatani, A | 1 |
| Ahlström, H; Axén, N; Gölander, CG; Häggman, M; Isotalo, T; Ladjevardi, S; Lennernäs, B; Lennernäs, H; Taari, K; Tammela, TL; Tolf, A; von Below, C; Wassberg, C; Weis, J | 1 |
| Culig, Z | 1 |
| Axén, N; Isotalo, T; Lennernäs, B; Lennernäs, H; Malmsten, LÅ; Sjögren, E; Taari, K; Tammela, TL | 1 |
| Hara, N; Ishizaki, F; Nishiyama, T; Takeda, K; Tasaki, M; Tomita, Y | 1 |
| Bilińska, B; Dulińska-Litewka, J; Górowska-Wójtowicz, E; Hejmej, A; Kamińska, A; Kotula-Balak, M; Laidler, P; Pardyak, L | 1 |
| Baniahmad, A; Eskelinen, H; Lehtovuori, PT; Nyrönen, TH; Roell, D; Söderholm, AA; Viiliäinen, J | 1 |
| Hara, S; Isaacs, JT; Ishioka, J; Kageyama, Y; Nishikawa, K; Tomura, A | 1 |
| Dubbink, HJ; Hersmus, R; Jenster, G; Lusher, SJ; Molier, M; Trapman, J; van de Wijngaart, DJ | 1 |
| Itoh, K; Kanayama, H; Kawabata, R; Oie, S; Oka, T; Takahashi, M | 1 |
| Bao, TY; Fu, Q; Gao, JY; Gao, XP; Lei, YH; Li, JQ; Li, YM; Liu, F; Qiu, JX; Shao, C; Shi, CH; Wang, JY; Wang, Y; Xue, W; Yang, ZY; Yuan, JL; Zhang, W; Zhang, YT | 1 |
| Dits, NF; Erkens-Schulze, S; Jenster, G; Marques, RB; van Ijcken, WF; van Weerden, WM | 1 |
| Andrieu, T; Baker, ME; Bertolini, R; Frey, BM; Frey, FJ; Nichols, SE; Setoud, R | 1 |
| Bartsch, G; Culig, Z; Godoy-Tundidor, S; Hobisch, A; Pfeil, K | 1 |
| Bonmassar, E; Faraoni, I; Missale, C; Rizzetti, MC; Sigala, S; Spano, P; Tognazzi, N | 1 |
| Chan, FL; Chang, C; Huang, J; Lee, YF; Lin, WJ; Messing, EM; Wilding, G | 1 |
| Lou, YR; Nazarova, N; Pennanen, P; Qiao, S; Tuohimaa, P | 1 |
| Aozasa, K; Chang, C; Chang, HC; Harada, Y; Kang, HY; Miyamoto, H; Nishimura, K; Nonomura, N; Okuyama, A; Shin, M; Ting, HJ; Tokizane, T; Yeh, S | 1 |
| Fujisawa, Y; Harano, M; Hida, T; Kano, M | 1 |
| Ishizuka, M; Kawada, M; Minamiguchi, K; Ohba, S; Takamoto, K | 1 |
| Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U | 1 |
| Chang, C; Hsu, CL; Hu, YC; Huang, J; Kim, E; Li, P; Lin, HK; Ni, J; Sampson, ER; Ting, HJ; Wang, L; Yeh, S; Yeh, SD | 1 |
| Bevan, CL; Cato, AC; Gamble, SC; Hanrahan, S; Hurst, HC; Totty, N; Waxman, J; Whitaker, HC | 1 |
| Lou, YR; Nazarova, N; Talonpoika, R; Tuohimaa, P | 1 |
| Ajayi, AA; Halushka, PV | 1 |
| Bechor, Y; Birman, A; Chisin, R; Even-Sapir, E; Fadeeva, L; Golan, E; Gozin, M; Gutman, M; Icar, A; Jacobson, O; Leibovitch, I; Marom, H; Mishani, E; Novak, N | 1 |
| Farla, P; Hersmus, R; Houtsmuller, AB; Trapman, J | 1 |
| Bondesson, U; Hedeland, M; Jönsson, M; Lennernäs, B; Lennernäs, H; Norlin, M; Tevell, A | 1 |
| Carlson, KE; Chisin, R; Elgavish, S; Even-Sapir, E; Gozin, M; Gutman, M; Jacobson, O; Katzenellenbogen, JA; Laky, D; Leibovitc, I; Mishani, E | 1 |
| Fuse, H; Hiyama, T; Ito, T; Kato, S; Kimura, K; Korenaga, S; Sakari, M | 1 |
| Hara, S; Hyochi, N; Isaacs, JT; Ishioka, J; Kageyama, Y; Kihara, K; Singh, P; Urushibara, M | 1 |
| Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S | 1 |
| Calabrò, M; Carruba, G; Castagnetta, LA; Farruggio, R; Miceli, MD; Oliveri, G; Pfeffer, U; Sorci, CM | 1 |
| Bartsch, G; Cato, AC; Culig, Z; Hobisch, A; Klocker, H; Peterziel, H; Radmayr, C; Stober, J | 1 |
| Carruba, G; Castagnetta, LA; Comito, L; D'Amico, D; Farruggio, R; Miceli, D; Montesanti, A; Polito, L | 1 |
| D'Eramo, G; Di Silverio, F; Felli, MP; Frati, L; Gulino, A; Lubrano, C; Maroder, M; Ravenna, L; Sciarra, F; Vacca, A | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Muzi, P; Vicentini, C | 1 |
| Dell'Acqua, G; Fattorossi, A; Iacopino, F; Marchetti, P; Pavone-Macaluso, M; Sica, G; van der Kwast, TH | 1 |
| Govindan, MV; Koutsilieris, M; Pagé, N; Warriar, N | 1 |
| Berrevoets, CA; Mulder, E; Veldscholte, J | 1 |
| Chang, C; Yeh, S | 1 |
| Batchelor, KW; Grant, ES; Habib, FK | 1 |
| deVere White, RW; French, FS; Gregory, CW; Gumerlock, PH; Hamil, KG; Harris, SE; Mohler, JL; Pretlow, TG; Sar, M; Sharief, Y; Tan, J; Wilson, EM; Zang, DY | 1 |
| Chang, C; Miyamoto, H; Yeh, S | 1 |
| Bartsch, G; Cronauer, MV; Culig, Z; Hittmair, A; Hobisch, A; Klocker, H; Radmayr, C; Zhang, J | 1 |
| Chang, C; Miyamoto, H; Wilding, G; Yeh, S | 1 |
| Chang, C; Lardy, H; Messing, E; Miyamoto, H; Yeh, S | 1 |
| Balk, SP; Bubley, GJ; Fenton, MA; Fertig, AM; Kolvenbag, G; Shuster, TD; Taplin, ME | 1 |
| Chang, C; Kang, HY; Lin, HK; Lin, MF; Thin, TH; Yeh, S | 1 |
| Fan, Z; Mendelsohn, J; Ye, D | 1 |
| Chang, C; Chang, HC; Fujimoto, N; Hu, YC; Huang, KE; Kang, HY; Lin, HK; Miyamoto, H; Mizokami, A; Nishimura, K; Rahman, M; Ting, HJ; Yeh, S | 1 |
| Jones, GR; Lyng, FM; Rommerts, FF | 1 |
| Bentel, JM; Buchanan, G; Greenberg, NM; Han, G; Harris, JM; Horsfall, DJ; Marshall, VR; Matusik, RJ; Moore, N; Nahm, HS; Tilley, WD; Yang, M | 1 |
| Andriani, F; Denner, L; Fang, B; Kagawa, S; Kasper, S; Li, X; Marcelli, M; Matusik, RJ; McPhaul, MJ; Nan, B; Weigel, NL; Yu, J | 1 |
| Chalmers, D; Kirk, D; Leake, RE; Lloyd, SN | 1 |
| de Launoit, Y; Dufour, M; Labrie, F; Simard, J; Veilleux, R | 1 |
| Arbusow, V; Bojar, H; Fittler, F; Klobeck, HG; Schulz, P; Wolf, D | 1 |
| Olea, N; Sakabe, K; Sonnenschein, C; Soto, AM | 1 |
| Becker, H; Donn, F; Schmoldt, A; Schulz, M | 1 |
| Bélanger, A; Couture, J; Cusan, L; Dupont, A; Giasson, M; Labrie, F | 1 |
| Mauvais-Jarvis, P; Mowszowicz, I; Portois, MC; Santen, RJ | 1 |
1 review(s) available for hydroxyflutamide and Prostatic Neoplasms
| Article | Year |
|---|---|
Targeting the androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Curcumin; Flutamide; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tosyl Compounds | 2014 |
4 trial(s) available for hydroxyflutamide and Prostatic Neoplasms
| Article | Year |
|---|---|
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
Topics: Aged; Androgen Antagonists; Delayed-Action Preparations; Flutamide; Humans; Injections, Intralesional; Male; Middle Aged; Prostatic Neoplasms | 2017 |
Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model.
Topics: Area Under Curve; Chemistry, Pharmaceutical; Delayed-Action Preparations; Flutamide; Half-Life; Humans; Male; Models, Biological; Prostate; Prostatic Neoplasms | 2014 |
[Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients].
Topics: Aged; Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Flutamide; Humans; Liver Function Tests; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Reference Values | 2004 |
Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Biotransformation; Chromatography, Liquid; Dogs; Flutamide; Glucuronidase; Humans; In Vitro Techniques; Male; Microsomes, Liver; Prostate; Prostatic Neoplasms; Rats; Spectrometry, Mass, Electrospray Ionization; Swine | 2006 |
67 other study(ies) available for hydroxyflutamide and Prostatic Neoplasms
| Article | Year |
|---|---|
Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Topics: Androgen Antagonists; Antineoplastic Agents, Alkylating; Binding, Competitive; Estramustine; Estrogens; Estrone; Genes, Reporter; HeLa Cells; Humans; Kinetics; Luciferases; Male; Metribolone; Mutagenesis; Nitrogen Mustard Compounds; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Transcriptional Activation; Transfection; Triamcinolone Acetonide; Tumor Cells, Cultured | 1998 |
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Indoles; Inhibitory Concentration 50; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Tumor Cells, Cultured | 2005 |
Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
Topics: Androgen Antagonists; Anilides; Animals; Bromine Radioisotopes; Fluorine Radioisotopes; Isotope Labeling; Ligands; Male; Mice; Neoplasm Transplantation; Nitriles; Prostatic Neoplasms; Radioligand Assay; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution; Tosyl Compounds | 2007 |
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
Topics: Administration, Oral; Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Drug Design; Humans; Isoindoles; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Structure-Activity Relationship; Tosyl Compounds; Tumor Cells, Cultured | 2008 |
4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Humans; Male; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Binding; Pyrroles; Receptors, Androgen | 2008 |
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Flufenamic Acid; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Tacrolimus Binding Proteins; Transcriptional Activation | 2009 |
Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.
Topics: Administration, Oral; Androgen Receptor Antagonists; Androgens; Animals; Azabicyclo Compounds; Dogs; Drug Design; Humans; Ligands; Male; Mice; Microsomes, Liver; Mutation; NIH 3T3 Cells; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Androgen; Structure-Activity Relationship; Substrate Specificity; Testosterone Propionate | 2009 |
Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Boranes; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen | 2010 |
Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Topics: 17-Hydroxysteroid Dehydrogenases; Androsterone; Enzyme Inhibitors; HEK293 Cells; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Structure-Activity Relationship | 2011 |
Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Mice; Models, Molecular; Molecular Structure; Phthalazines; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship | 2015 |
Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
Topics: Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Cell Proliferation; Coumarins; Flutamide; Humans; Male; Molecular Structure; Mutation; Nonsteroidal Anti-Androgens; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2020 |
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds | 2016 |
Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways.
Topics: Androgen Antagonists; Antigens, CD; beta Catenin; Cadherins; Cell Line, Tumor; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen | 2017 |
Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Flutamide; Humans; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Pyridines; Tosyl Compounds | 2008 |
Suppression of mutant androgen receptors by flutamide.
Topics: Androgen Antagonists; Androgens; Binding, Competitive; Cell Line, Tumor; Dihydrotestosterone; Flutamide; Humans; Luciferases; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Transcriptional Activation | 2009 |
Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.
Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Line, Tumor; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Humans; Hydrocortisone; Hydrophobic and Hydrophilic Interactions; Male; Mutation; Nitriles; Progesterone; Prostatic Neoplasms; Protein Structure, Secondary; Receptors, Androgen; Steroids; Structure-Activity Relationship; Tosyl Compounds | 2010 |
Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Flutamide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Thymidylate Synthase; Tosyl Compounds | 2011 |
Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.
Topics: Androgen Antagonists; Drug Resistance, Neoplasm; Flutamide; Gene Expression; Gene Expression Profiling; Humans; Male; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 2; Nuclear Receptor Coactivators; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 2011 |
Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Flutamide; Gene Expression Profiling; Humans; Male; Metribolone; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2011 |
A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Topics: Androgen Antagonists; Animals; Binding, Competitive; Carbamates; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Dihydrotestosterone; Drug Screening Assays, Antitumor; Flutamide; Humans; Male; Models, Molecular; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Structure-Activity Relationship; Transcriptional Activation | 2011 |
Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Chloramphenicol; Cyclic AMP-Dependent Protein Kinases; DNA Primers; Enzyme Inhibitors; Flavonoids; Flutamide; Growth Inhibitors; Humans; Interleukin-6; Male; Nitriles; Oncostatin M; Peptides; Prostatic Neoplasms; Receptors, Androgen; Receptors, Cytokine; Receptors, Oncostatin M; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tosyl Compounds; Transfection; Tumor Cells, Cultured | 2002 |
Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145.
Topics: Androgen Antagonists; Androgens; Apoptosis; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Gene Expression; Humans; Male; Nerve Growth Factor; Prostatic Neoplasms; Receptor, Nerve Growth Factor; Receptors, Androgen; RNA, Messenger; Telomerase; Tumor Cells, Cultured | 2002 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptors, Androgen; Substance Withdrawal Syndrome; Tyrphostins | 2002 |
Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Topics: Androgen Antagonists; Anilides; Calcitriol; Cerulenin; Cycloheximide; Down-Regulation; Enzyme Inhibitors; Fatty Acid Synthases; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 2003 |
Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.
Topics: Animals; Cloning, Molecular; COS Cells; Dihydrotestosterone; Flutamide; Gelsolin; Humans; Male; Mice; Prostatic Neoplasms; Receptors, Androgen; Transcriptional Activation | 2003 |
Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Topics: Active Transport, Cell Nucleus; Base Sequence; Cell Division; Cell Line, Tumor; Drug Interactions; Flutamide; Humans; Interphase; Male; Peptide Fragments; Prostatic Neoplasms; Receptors, Androgen; Transcriptional Activation; Transfection | 2004 |
Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures.
Topics: Adenocarcinoma; Androgen Antagonists; Apoptosis; Cell Division; Cell Survival; Cysteine Proteinase Inhibitors; Drug Interactions; Flutamide; Humans; Leupeptins; Male; Oligopeptides; Prostatic Neoplasms; Protease Inhibitors; Tumor Cells, Cultured | 2004 |
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
Topics: Amino Acid Sequence; Androgen Antagonists; Animals; Blotting, Western; Cell Nucleus; Chlorocebus aethiops; Consensus Sequence; COS Cells; Drug Stability; Fluorescent Antibody Technique; Flutamide; Gene Expression; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Transplantation; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Structure-Activity Relationship; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Two-Hybrid System Techniques | 2004 |
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Topics: Adenosine Triphosphate; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Cell Nucleus; COS Cells; Cytoplasm; Cytoskeleton; Electrophoresis, Gel, Two-Dimensional; Flutamide; Humans; Immunoblotting; Male; Mass Spectrometry; Microscopy, Confocal; Microscopy, Fluorescence; Nitriles; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Subcellular Fractions; Tosyl Compounds; Transfection | 2004 |
5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Calcitriol; Cycloheximide; Cytochrome P-450 Enzyme System; Dihydrotestosterone; Drug Interactions; Flutamide; Gene Expression Regulation, Enzymologic; Humans; Male; Nitriles; Prostatic Neoplasms; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Steroid Hydroxylases; Tosyl Compounds; Tumor Cells, Cultured; Vitamin D3 24-Hydroxylase | 2005 |
Castration reduces platelet thromboxane A2 receptor density and aggregability.
Topics: Aged; Androgen Antagonists; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Castration; Cross-Sectional Studies; Flutamide; Humans; Male; Middle Aged; Platelet Aggregation; Prostatic Neoplasms; Receptors, Thromboxane A2, Prostaglandin H2; Testosterone | 2005 |
Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives.
Topics: Androgen Antagonists; Fluorine Radioisotopes; Flutamide; Humans; Male; Prostatic Neoplasms; Radionuclide Imaging | 2005 |
Antiandrogens prevent stable DNA-binding of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Computer Simulation; DNA; DNA-Binding Proteins; DNA, Neoplasm; Flutamide; Green Fluorescent Proteins; Humans; Liver Neoplasms; Male; Metribolone; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Tosyl Compounds | 2005 |
Chiral dimethylamine flutamide derivatives--modeling, synthesis, androgen receptor affinities and carbon-11 labeling.
Topics: Carbon Radioisotopes; Flutamide; Humans; Isotope Labeling; Male; Models, Molecular; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Receptors, Androgen | 2006 |
Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
Topics: Androgens; Anilides; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flutamide; HeLa Cells; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Receptors, Interferon; Tosyl Compounds; Transcriptional Activation | 2007 |
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Topics: Allylestrenol; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Cyproterone Acetate; Flutamide; Humans; Imidazolidines; Male; Models, Molecular; Mutagenesis, Site-Directed; Neoplasms, Hormone-Dependent; Nitriles; Plasmids; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Testosterone; Tosyl Compounds; Transcription, Genetic; Transfection | 2007 |
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Fluorescent Antibody Technique; Flutamide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; NF-kappa B; Nitrobenzenes; Polymerase Chain Reaction; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Transfection; Tumor Cells, Cultured; Up-Regulation | 2008 |
Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor.
Topics: Androgen Antagonists; Base Sequence; Breast Neoplasms; Cell Division; Cell Line; Cell Nucleus; Cytosol; Dihydrotestosterone; DNA Primers; DNA, Neoplasm; Estradiol; Female; Flutamide; Gene Expression; Humans; Kinetics; Male; Molecular Sequence Data; Polymerase Chain Reaction; Prostate-Specific Antigen; Prostatic Neoplasms; Radioligand Assay; Receptors, Estradiol; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding.
Topics: Amino Acid Sequence; Androgen Antagonists; Animals; Base Sequence; Binding Sites; Flutamide; Haplorhini; Ligands; Male; Methionine; Molecular Sequence Data; Mutation; Prostatic Neoplasms; Protein Binding; Protein Conformation; Receptors, Androgen; Structure-Activity Relationship; Transcriptional Activation; Transfection; Valine | 1995 |
Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells.
Topics: Androgen Antagonists; Cadherins; Dihydrotestosterone; Estradiol; Estrogen Antagonists; Flutamide; Fulvestrant; Gonadal Steroid Hormones; Humans; Immunoblotting; Immunohistochemistry; Male; Prostatic Neoplasms | 1995 |
Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP.
Topics: Androgen Antagonists; Blotting, Northern; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Flutamide; Gene Expression; Humans; Male; Metribolone; Prostatic Neoplasms; Protein Binding; Radioimmunoassay; Receptors, Androgen; RNA, Messenger; Time Factors; Tumor Cells, Cultured | 1995 |
Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro.
Topics: Androgen Antagonists; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Finasteride; Flutamide; Humans; Linear Models; Male; Prostatic Neoplasms; Testosterone; Tumor Cells, Cultured | 1995 |
Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.
Topics: Androgen Antagonists; Androgens; Cell Cycle; Cell Division; Dihydrotestosterone; Drug Resistance; Flutamide; Humans; Immunohistochemistry; Interferon-beta; Male; Prostatic Neoplasms; Receptors, Androgen; Tumor Cells, Cultured | 1994 |
Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Topics: Amino Acid Sequence; Androgen Antagonists; Binding, Competitive; Blotting, Western; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Gene Expression Regulation, Viral; Humans; Imidazoles; Imidazolidines; Male; Mammary Tumor Virus, Mouse; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1994 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Western; Cell Line; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Metribolone; Mutagenesis, Site-Directed; Nitriles; Point Mutation; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Threonine; Tosyl Compounds; Transcription, Genetic; Transfection; Transformation, Genetic; Tumor Cells, Cultured | 1993 |
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.
Topics: Amino Acid Sequence; Base Sequence; Blotting, Northern; Cell Line; Chloramphenicol O-Acetyltransferase; Cloning, Molecular; Dihydrotestosterone; DNA-Binding Proteins; Flutamide; Humans; Male; Molecular Sequence Data; Nuclear Receptor Coactivators; Oncogene Proteins; Prostate; Prostatic Neoplasms; Receptors, Androgen; Receptors, Steroid; Recombinant Proteins; RNA, Messenger; Testosterone; Trans-Activators; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1996 |
Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression.
Topics: Androgen Antagonists; Androgens; Base Sequence; Blotting, Northern; Cell Division; Dihydrotestosterone; DNA, Neoplasm; Dose-Response Relationship, Drug; Down-Regulation; Epithelium; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Sequence Data; Polymerase Chain Reaction; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1996 |
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Topics: Androgen Antagonists; Animals; Chromosome Mapping; Dehydroepiandrosterone; Epithelium; Estradiol; Flutamide; Haplorhini; Humans; Ligands; Male; Mutation; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic; Transcriptional Activation; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Hydroxyflutamide may not always be a pure antiandrogen.
Topics: Androgen Antagonists; Flutamide; Humans; Male; Nuclear Receptor Coactivators; Oncogene Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Trans-Activators; Transcription Factors | 1997 |
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Topics: Androgen Antagonists; Anilides; Bucladesine; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclic AMP; Flutamide; Genes, Reporter; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Metribolone; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Testosterone Congeners; Tosyl Compounds; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1997 |
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Androgens; Anilides; Cyproterone Acetate; Drug Interactions; Flutamide; Humans; Imidazoles; Male; Mifepristone; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Binding; Protein Conformation; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
Topics: Androgens; Androstane-3,17-diol; Androstenediol; Anilides; Flutamide; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Steroids; Testosterone; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Topics: Amino Acid Substitution; Androgen Antagonists; Androgens; Androstenedione; Animals; beta-Galactosidase; Cell Line; Dihydrotestosterone; Estradiol; Flutamide; Genes, Reporter; Imidazoles; Imidazolidines; Luciferases; Male; Point Mutation; Progesterone; Prostatic Neoplasms; Receptors, Androgen; Recombinant Fusion Proteins; Transfection | 1997 |
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
Topics: Androgen Antagonists; Androgens; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Flavonoids; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Mutagenesis, Site-Directed; Nuclear Receptor Coactivators; Oncogene Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Trans-Activators; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Tyrphostins | 1999 |
Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Base Sequence; Dihydrotestosterone; Estradiol; Estramustine; Flutamide; Humans; Ligands; Male; Molecular Sequence Data; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tosyl Compounds; Tumor Cells, Cultured | 1999 |
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cycloheximide; Dihydrotestosterone; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flutamide; Humans; Male; Metribolone; Microtubule-Associated Proteins; Prostatic Neoplasms; Protein Synthesis Inhibitors; Receptors, Androgen; Testosterone Congeners; Trastuzumab; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.
Topics: Androgen Antagonists; Carrier Proteins; Flutamide; Gonadal Steroid Hormones; Histone Acetyltransferases; Humans; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Male; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Receptors, Androgen; Trans-Activators; Transcription Factors; Tumor Cells, Cultured | 1999 |
Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations.
Topics: Androgen Antagonists; Androgens; Animals; Calcium Signaling; Cell Line; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Flutamide; Gap Junctions; Humans; Kinetics; Male; Metribolone; Prostate; Prostatic Neoplasms; Rats; Rats, Wistar; Sertoli Cells; Testosterone; Tumor Cells, Cultured | 2000 |
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Binding Sites; Cell Line; COS Cells; Dihydrotestosterone; DNA; Estradiol; Flutamide; Humans; Male; Mice; Mice, Transgenic; Models, Molecular; Mutagenesis; Mutation; Progesterone; Prostatic Neoplasms; Protein Structure, Secondary; Receptors, Androgen; Structure-Activity Relationship; Transcriptional Activation; Transfection | 2001 |
Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
Topics: Adenoviridae; Androgen Antagonists; Androgen-Binding Protein; Animals; Apoptosis; Arabidopsis Proteins; bcl-2-Associated X Protein; Blotting, Western; DNA-Binding Proteins; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Promoter Regions, Genetic; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 2001 |
Local hyperthermia for prostatic disease: in vitro studies on human prostatic cancer cell lines.
Topics: Cell Division; Cell Survival; Dihydrotestosterone; DNA, Neoplasm; Flutamide; Humans; Hyperthermia, Induced; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 1992 |
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
Topics: Androgens; Androstane-3,17-diol; Binding, Competitive; Cell Cycle; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Antagonism; Estradiol; Estrogen Antagonists; Estrone; Flow Cytometry; Flutamide; Humans; In Vitro Techniques; Male; Metribolone; Piperidines; Prostatic Neoplasms; Raloxifene Hydrochloride; Tamoxifen; Testosterone; Time Factors; Tumor Cells, Cultured | 1991 |
The synthetic androgen mibolerone induces transient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line.
Topics: Androgen Antagonists; Androgens; Cell Division; Cell Transformation, Neoplastic; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Flutamide; Humans; Male; Nandrolone; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Tumor Cells, Cultured | 1990 |
The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP.
Topics: Androgens; Antibodies; Cell Division; Dihydrotestosterone; Estradiol; Flutamide; Humans; Male; Nandrolone; Prostatic Neoplasms; Receptors, Androgen; Testosterone Congeners; Tumor Cells, Cultured | 1990 |
The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.
Topics: Administration, Oral; Anilides; Flutamide; Humans; Male; Prostatic Neoplasms | 1988 |
Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
Topics: Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |
Androgen dependence of the Dunning R3327G cell line in monolayer culture.
Topics: Androgen Antagonists; Androgens; Animals; Cell Division; Cell Line; Dihydrotestosterone; Flutamide; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1987 |